Trace-mIDH

The analysis of the binding specificity of the newly developed tracer is carried out ex vivo on tumor tissue from patients with chondrosarcoma and gliomas and investigates whether the mIDH inhibitor AG-120 labeled with 18F is suitable for the specific visualization of the mutated enzyme in tissue sections. Testing on tissues with different IDH mutations allows the assessment of the binding specificity depending on the respective IDH mutation. The results allow an evaluation of the potential suitability of [18F]AG-120 for non-invasive diagnostics for the localization of an mIDH-positive tumor and potential recurrences/metastases in the patient.

{ "short_title": "Trace-mIDH", "data_mode": "900", "data_mode_number": "000002412", "official_title": "In-vitro-Bindungsanalyse von 18F-markiertem Ivosidenib als neuartiger PET-Tracer f\u00fcr IDH1-mutierte Chondrosarkome und Gliome (Trace-mIDH)", "accrual_state": "running", "therapeutic_value": "nonTherapeutic", "therapieansatz_value": "not_applicable", "therapieintervention_value": "not_applicable", "therapielinie_value": "not_applicable", "ctgov_number": null, "eudract_number": null, "general_contact_email": "sarkome@ukdd.de", "general_contact_phone": "+49 351-4583777", "hauptpruefer_dd_name": "Prof. Dr. med. Klaus-Dieter Schaser", "description_laie_de": "Die Analyse der Bindungsspezifit\u00e4t des neu entwickelten Tracers erfolgt ex vivo an Tumorgewebe von Patienten mit Chondrosarkomen und Gliomen und untersucht, ob sich der mit 18F markierte mIDH-Inhibitor AG-120 zur spezifischen Visualisierung des mutierten Enzyms in Gewebeschnitten eignet. Die Testung an Geweben mit nachgewiesenen unterschiedlichen IDH-Mutationen erlaubt die Beurteilung der Bindungsspezifit\u00e4t in Abh\u00e4ngigkeit von der jeweiligen IDH-Mutation. Die Ergebnisse erm\u00f6glichen eine Bewertung der potentiellen Eignung von [18F]AG-120 f\u00fcr die nicht-invasive Diagnostik zur Lokalisation eines mIDH-positiven Tumors und potenzieller Rezidive/Metastasen im Patienten.", "description_laie_en": "The analysis of the binding specificity of the newly developed tracer is carried out ex vivo on tumor tissue from patients with chondrosarcoma and gliomas and investigates whether the mIDH inhibitor AG-120 labeled with 18F is suitable for the specific visualization of the mutated enzyme in tissue sections. Testing on tissues with different IDH mutations allows the assessment of the binding specificity depending on the respective IDH mutation. The results allow an evaluation of the potential suitability of [18F]AG-120 for non-invasive diagnostics for the localization of an mIDH-positive tumor and potential recurrences/metastases in the patient.", "description_expert_de": "Die Analyse der Bindungsspezifit\u00e4t des neu entwickelten Tracers erfolgt ex vivo an Tumorgewebe von Patienten mit Chondrosarkomen und Gliomen und untersucht, ob sich der mit 18F markierte mIDH-Inhibitor AG-120 zur spezifischen Visualisierung des mutierten Enzyms in Gewebeschnitten eignet. Die Testung an Geweben mit nachgewiesenen unterschiedlichen IDH-Mutationen erlaubt die Beurteilung der Bindungsspezifit\u00e4t in Abh\u00e4ngigkeit von der jeweiligen IDH-Mutation. Die Ergebnisse erm\u00f6glichen eine Bewertung der potentiellen Eignung von [18F]AG-120 f\u00fcr die nicht-invasive Diagnostik zur Lokalisation eines mIDH-positiven Tumors und potenzieller Rezidive/Metastasen im Patienten.", "description_expert_en": "The analysis of the binding specificity of the newly developed tracer is carried out ex vivo on tumor tissue from patients with chondrosarcoma and gliomas and investigates whether the mIDH inhibitor AG-120 labeled with 18F is suitable for the specific visualization of the mutated enzyme in tissue sections. Testing on tissues with different IDH mutations allows the assessment of the binding specificity depending on the respective IDH mutation. The results allow an evaluation of the potential suitability of [18F]AG-120 for non-invasive diagnostics for the localization of an mIDH-positive tumor and potential recurrences/metastases in the patient.", "rechtsgrundlage_value": "BO", "phase_amg_value": null, "main_cat_id": 9, "sub_cat_id": 45 }